Clinical trials: Ulcerative Colitis (UC)
Active Ulcerative Colitis
TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC)
The purpose of the trial is to proof whether TID 1000 mg mesalazine is non-inferior to TID 2x 500 mg mesalazine in the treatment of patients with acute ulcerative colitis
- Trial name
- NCT01745770
- Testing
- Mesalazine - TID 1000 mg, Mesalazine - TID 2x 500 mg
- Where
- Germany
- Volunteers
- 306 people
- Sponsor
- Dr. Falk Pharma GmbH
Ulcerative Colitis (UC)
A Study of Cizutamig for Patients With Ulcerative Colitis
A Study of Cizutamig for Patients with Ulcerative Colitis
- Trial name
- NCT07353450
- Testing
- cizutamig
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Ruijin Hospital
Ulcerative Colitis
A Study of Abatacept in Patients With Active Ulcerative Colitis
The purpose of this clinical research study is to learn if abatacept can improve signs and symptoms of active ulcerative colitis in patients who have not had an adequate response to other therapies.
- Trial name
- NCT00410410
- Testing
- abatacept (ABA), abatacept
- Where
- 143 sites in United States, Australia and 17 more
- Volunteers
- 591 people
- Sponsor
- Bristol-Myers Squibb
Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC)
Investigation of Vancomycin Efficacy in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis
This clinical trial tests if oral vancomycin can safely treat active ulcerative colitis (UC) in adults who also have primary sclerosing cholangitis (PSC), a liver condition.
- Trial name
- DRIVE-UP (NCT07341282)
- Testing
- Vancomycin (blinded), Vancomycin (open-label extension)
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- McMaster University
Ulcerative Colitis (UC)
hucMSCs Exosomes for the Treatment of Active Ulcerative Colitis
To evaluate the safety and efficacy of hUC-MSCs-Exos in the treatment of ulcerative colitis.
- Trial name
- NCT06853522
- Testing
- exosomes derived from human umbilical cord mesenchymal stem cells, saline +5% albumin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai East Hospital
Ulcerative Colitis
Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)
Assess the body's reaction to dose-response relationship for the adalimumab/Methotrexate interaction in subjects with moderately to severely active ulcerative colitis.
- Trial name
- NCT01716039
- Testing
- MTX 12.5, MTX 25, Adalimumab
- Volunteers
- 22 people
- Sponsor
- Alimentiv Inc.
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC)
Anal Human Papillomavirus in Inflammatory Bowel Disease Study
This is an observational cohort study with two time points (baseline and after at least 6 months of treatment with a non-corticosteroid immunosuppressive agent for inflammatory bowel disease (IBD)).
- Conditions
- Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease (CD), Anal Human Papillomavirus
- Trial name
- AnalHPV&IBD (NCT01364896)
- Testing
- Venous blood samples, anal swab samples, vaginal swab samples, high resolution anoscopy (HRA), anal biopsy samples
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Pittsburgh
Ulcerative Colitis, Active Moderate
Adacolumn in Refractory UC Patients Trial
The objectives of the study are to observe and document the efficacy and safety of 5 or more Adacolumn treatments, administered once weekly over 5 or more weeks, in a specific subset of ulcerative colitis patients.
- Trial name
- ART (NCT01481142)
- Testing
- (GMA) Adsorptive Apheresis
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Ulcerative Colitis (UC)
The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC
This study will evaluate the efficacy and safety of 627 in patients with UC.
- Trial name
- NCT07507513
- Testing
- 627
- Where
- China
- Volunteers
- 288 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
IBD (Inflammatory Bowel Disease), Crohn Disease (CD)
FAPi-PET Imaging of in Vivo Fibrosis in Inflammatory Bowel Disease Patients
Our main objective is to evaluate the feasibility of 68Ga-FAPi PET/CT in detecting intestinal fibrosis in patients with IBD. To this end, we will determine 68Ga-FAPi uptake in IBD in relation to cellular FAP expression in…
- Conditions
- IBD (Inflammatory Bowel Disease), Crohn Disease (CD), Ulcerative Colitis (UC)
- Trial name
- PIMAFI (NCT06604260)
- Testing
- 68Ga-FAPi-46
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Dalia Lartey
Inflammatory Bowel Disease (IBD), Crohn&Amp;#39;s Disease (CD)
Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease
The goal of this retrospective study is to learn about dosing patterns in patients starting subcutaneous vedolizumab administration and patient outcomes after starting subcutaneous administration.
- Conditions
- Inflammatory Bowel Disease (IBD), Crohn&Amp;#39;s Disease (CD), Ulcerative Colitis (UC)
- Trial name
- NCT07123350
- Testing
- Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Vanderbilt University Medical Center
Crohn's Disease (CD), Ulcerative Colitis (UC)
Supplementation of Vitamin D3 in Patients With Inflammatory Bowel Diseases and Hypovitaminosis D
This study aims to evaluate the effect of vitamin D3 supplementation on disease activity and quality of life in IBD patients deficient in vitamin D, and also help determine the optimal dose of vitamin D3 for them.
- Trial name
- NCT01877577
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Crohn Disease, Ulcerative Colitis
Characterization of CD Responders to Vedolizumab
The purpose of this study is to characterize which patients with Crohn's disease are likely to respond to standard of care to vedolizumab therapy.
- Trial name
- NCT04909359
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- University of Miami
Inflammatory Bowel Disease
Johns Hopkins Crohn's Disease and Ulcerative Colitis Study
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a idiopathic, chronic and frequently disabling inflammatory disorder of the intestines characterized by a dysregulated mucosal…
- Trial name
- NCT01169207
- Where
- United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Ulcerative Colitis
Capsulized Fecal Microbiota Transplantation in Pediatric Ulcerative Colitis Patients
Fecal Microbiota Transplantation(FMT) - reconstitution of normal flora by a stool transplant from a healthy individual, is increasingly being recognized as a therapeutic modality for diseases that are associated with gut…
- Trial name
- FMT UC (NCT03582969)
- Testing
- Fecal transplantation
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Assaf-Harofeh Medical Center
Ulcerative Colitis
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of vixarelimab compared with placebo in participants with moderate to severe UC who have demonstrated inadequate response to, loss of…
- Trial name
- NCT06137183
- Testing
- Vixarelimab
- Where
- 65 sites in United States, Brazil and 10 more
- Volunteers
- 79 people
- Sponsor
- Genentech, Inc.
Ulcerative Colitis
Study of Cimzia for the Treatment of Ulcerative Colitis
The purpose of this study is to determine if Cimzia (certolizumab pegol) is an effective treatment for patients with Ulcerative colitis.
- Trial name
- UC CIMZIA (NCT01090154)
- Testing
- Cimzia
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- University of Washington
Ulcerative Colitis (UC)
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
The Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XmAb942 in healthy volunteers (Parts A and B).
- Trial name
- NCT06619990
- Testing
- XmAb942
- Where
- 98 sites in United States, Argentina and 13 more
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Xencor, Inc.
Ulcerative Colitis
PRognOstiC valuE of rEd Density in Ulcerative Colitis
Observational prospective multicenter study: baseline assessement of the disease activity by an automated endoscopic tool and follow up of 52 weeks to evaluate sustained clinical remission.
- Trial name
- PROCEED-UC (NCT04408703)
- Testing
- Red Density
- Where
- 2 sites in Belgium
- Volunteers
- 243 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Colitis
Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis
GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis (GOAL-ARC). A nationwide multi-centred randomised controlled trial (RCT) investigating the use of GLM dose adjustment in ulcerative colitis (UC).
- Trial name
- GOAL-ARC (NCT02687724)
- Testing
- Golimumab (GLM)
- Where
- Ireland
- Volunteers
- 136 people
- Sponsor
- University College Dublin